04:01 AM EDT, 09/13/2024 (MT Newswires) -- Bicara Therapeutics (BCAX) said late Thursday it priced its initial public offering of 17.5 million common shares at $18 apiece.

The gross proceeds to Bicara Therapeutics will likely be about $315 million, excluding any exercise of the underwriters' option to purchase additional shares. The company granted underwriters a 30-day option to purchase up to about 2.6 million additional shares.

Bicara expects the shares to begin trading on the Nasdaq Global Market on Friday under the "BCAX" ticker. The offering will probably close, subject to conditions, on Sept. 16.